TY - JOUR
T1 - Expression of Secretory Phospholipase A2 Group IIa in Breast Cancer and Correlation to Prognosis in a Cohort of Advanced Breast Cancer Patients
AU - Jespersen, Sofie S
AU - Stovgaard, Elisabeth S
AU - Nielsen, Dorte
AU - Christensen, Troels D
AU - Buhl, Anna S K
AU - Christensen, Ib J
AU - Balslev, Eva
PY - 2021/1
Y1 - 2021/1
N2 - Secreted phospholipase A2 group IIa (sPLA2-IIa) has been shown to promote tumor genesis and cell proliferation. The properties of this group of enzymes are utilized in liposomal drug delivery of chemotherapy. sPLA2-IIa is also under investigation as a possible treatment target in itself, and as a prognostic marker. The expression of sPLA2-IIa in breast cancer has not been examined extensively, and never using immunohistochemistry. We sought to investigate the expression of sPLA2-IIa in a cohort of advanced breast cancer patients with correlation to known clinicopathologic risk factors and survival. Material from 525 breast cancer patients (426 primary tumors and 99 metastases or local recurrences) was examined for sPLA2-IIa expression using immunohistochemistry. Out of these, 262 showed expression of sPLA2-IIa. We found that there was no correlation to clinicopathologic characteristics, and no impact of sPLA2-IIa expression on prognosis. However, we found that a large proportion of patients in our study had high levels of sPLA2-IIa expression, and that sPLA2-IIa was equally expressed in primary tumors and metastases. These findings may be significant in the future development of liposomal drug delivery or targeted sPLA2-IIa treatment.
AB - Secreted phospholipase A2 group IIa (sPLA2-IIa) has been shown to promote tumor genesis and cell proliferation. The properties of this group of enzymes are utilized in liposomal drug delivery of chemotherapy. sPLA2-IIa is also under investigation as a possible treatment target in itself, and as a prognostic marker. The expression of sPLA2-IIa in breast cancer has not been examined extensively, and never using immunohistochemistry. We sought to investigate the expression of sPLA2-IIa in a cohort of advanced breast cancer patients with correlation to known clinicopathologic risk factors and survival. Material from 525 breast cancer patients (426 primary tumors and 99 metastases or local recurrences) was examined for sPLA2-IIa expression using immunohistochemistry. Out of these, 262 showed expression of sPLA2-IIa. We found that there was no correlation to clinicopathologic characteristics, and no impact of sPLA2-IIa expression on prognosis. However, we found that a large proportion of patients in our study had high levels of sPLA2-IIa expression, and that sPLA2-IIa was equally expressed in primary tumors and metastases. These findings may be significant in the future development of liposomal drug delivery or targeted sPLA2-IIa treatment.
KW - Adult
KW - Aged
KW - Aged, 80 and over
KW - Biomarkers, Tumor/biosynthesis
KW - Breast Neoplasms/enzymology
KW - Disease-Free Survival
KW - Female
KW - Gene Expression Regulation, Enzymologic
KW - Gene Expression Regulation, Neoplastic
KW - Group II Phospholipases A2/biosynthesis
KW - Humans
KW - Middle Aged
KW - Neoplasm Proteins/biosynthesis
KW - Prospective Studies
KW - Survival Rate
UR - http://www.scopus.com/inward/record.url?scp=85085334795&partnerID=8YFLogxK
U2 - 10.1097/PAI.0000000000000854
DO - 10.1097/PAI.0000000000000854
M3 - Journal article
C2 - 32217848
SN - 1541-2016
VL - 29
SP - e5-e9
JO - Applied Immunohistochemistry and Molecular Morphology
JF - Applied Immunohistochemistry and Molecular Morphology
IS - 1
ER -